02 December 2021 | Online: GMT (UTC+0)
Our 3D Cell Culture symposium incorporates key trends and innovative technologies to accelerate the adoption of 3D models in preclinical research via advanced development, validation and application strategies.
The programme brings together international pharmaceutical organisations, leading biotech companies and globally renowned academic institutions specialising in 3D Cell Culture
Access the conference brochure for presentation details, topic areas and confirmed speakers for our Virtual Symposium: 3D Cell Culture.
Registration for Virtual Symposium: 3D Cell Culture is now open. Please click the button below to register for this event.
Our LinkedIn group aims to foster discussion and collaboration between experts interested in the latest tools and strategies for 3D Cell Culture development and application.
Attendees representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions working within 3D Cell Culture.
Morning Session:
3D Culture Models & Technologies
Afternoon Session:
3D Cell Culture Applications
The Symposium brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data and industry perspectives.
Below are featured past speakers from 2020’s Cell Series UK: Virtual
AstraZeneca
University of Leuven
TreeFrog Therapeutics
AstraZeneca
Hubrecht Organoid Technology
International Serum Industry Association (ISIA)
Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of virtual, remote experiences.
We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.
ABL Inc, is a leading CDMO and CRO harnessing decades of pioneering science and manufacturing expertise to drive the development of innovative therapies and vaccines. ABL has extensive experience working with diverse organizations – including industry, government, and academic entities – to support their quest in improving public health. ABL Inc. –a subsidiary of the French bioindustrial group Institut Mérieux, which fights against infectious diseases and cancers, through the complementary approaches of its companies in the fields of diagnosis, immunotherapy, food safety and nutrition –maintains global GMP facilities meeting U.S. and European regulatory standards, providing cGMP biomanufacture of virus-based oncolytic therapies, gene therapies, vaccines, and protein-based immunotherapeutic products. ABL’s CDMO services include bulk drug substance, live virus fill/finish of drug product, process and assay development, and bioanalytical testing.
As a CRO, ABL’s immunologists use an integrated array of optimized immunology and molecular laboratory assay platforms, to extract immunological correlates of activity and response in both preclinical studies and clinical trials. To stay informed on the latest updates, please follow us on LinkedIn, Twitter and Facebook and subscribe to our mailing list.
ABL Inc, is a leading CDMO and CRO harnessing decades of pioneering science and manufacturing expertise to drive the development of innovative therapies and vaccines. ABL has extensive experience working with diverse organizations – including industry, government, and academic entities – to support their quest in improving public health. ABL Inc. –a subsidiary of the French bioindustrial group Institut Mérieux, which fights against infectious diseases and cancers, through the complementary approaches of its companies in the fields of diagnosis, immunotherapy, food safety and nutrition –maintains global GMP facilities meeting U.S. and European regulatory standards, providing cGMP biomanufacture of virus-based oncolytic therapies, gene therapies, vaccines, and protein-based immunotherapeutic products. ABL’s CDMO services include bulk drug substance, live virus fill/finish of drug product, process and assay development, and bioanalytical testing.
As a CRO, ABL’s immunologists use an integrated array of optimized immunology and molecular laboratory assay platforms, to extract immunological correlates of activity and response in both preclinical studies and clinical trials. To stay informed on the latest updates, please follow us on LinkedIn, Twitter and Facebook and subscribe to our mailing list.
